Kisspeptin-10

Kisspeptin-10 Molecular Structure & Chemical Properties

Kisspeptin-10 represents the smallest biologically active fragment of the kisspeptin family and has emerged as one of the most extensively studied neuropeptides in reproductive neuroendocrinology research over the past two decades. Originally derived from the KISS1 gene product identified as a metastasis suppressor in 1996, kisspeptin-10 peptide encompasses the C-terminal decapeptide sequence shared by all kisspeptin isoforms and serves as the minimal sequence necessary for full agonistic activity at the KISS1 receptor. Distinguished by its potent stimulatory effects on gonadotropin-releasing hormone secretion, kisspeptin-10 has been investigated in multiple species including rodents, primates, and humans, with research demonstrating its critical role in regulating puberty onset, reproductive function, and potentially broader metabolic and behavioral processes. While longer kisspeptin fragments exhibit greater plasma stability, kisspeptin-10’s shorter structure enables more rapid onset of action and has facilitated the development of both agonist and antagonist analogs for pharmaceutical applications.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide features a characteristic arginine-phenylalanine amide (RF-NH2) motif at its C-terminus, which is conserved across all members of the RF-amide peptide family and is critical for receptor binding and activation. The five C-terminal amino acids, particularly residues at positions 6, 8, 9, and 10 of the decapeptide sequence, appear essential for full agonistic activity at the human KISS1 receptor.

Kisspeptin-10 Mechanism of Action

Kisspeptin-10 peptide exerts its biological effects primarily through activation of the KISS1 receptor (also known as GPR54), a G protein-coupled receptor that serves as the master regulator of the hypothalamic-pituitary-gonadal axis. The peptide’s mechanism involves multiple interconnected signaling cascades that ultimately drive gonadotropin-releasing hormone secretion and coordinate reproductive function with metabolic status and developmental stage.

Primary Cellular Pathways

KISS1R/Gq Signaling – Hypothalamic GnRH Activation

Research demonstrates that kisspeptin-10 binds to KISS1R with high affinity (Ki approximately 2-3 nM), activating Gq/11-coupled signaling pathways that represent the primary mechanism of action. This activation triggers:

• Phospholipase C (PLC) stimulation leading to production of diacylglycerol and inositol trisphosphate
• Intracellular calcium mobilization essential for neuronal depolarization and neurotransmitter release
• ERK1/2 and p38 MAPK phosphorylation involved in cellular signaling and gene expression
• Direct stimulation of GnRH neurons in the hypothalamus, with more than 90% of GnRH neurons expressing KISS1R in rodent models

Studies using GnRH antagonists have demonstrated that blockade of GnRH actions completely abolishes kisspeptin-10’s ability to stimulate gonadotropin secretion, confirming its primary action through the hypothalamic GnRH system rather than direct pituitary effects.

Neurokinin B and Dynorphin Interactions – Pulsatile GnRH Release

Kisspeptin neurons in the arcuate nucleus co-express neurokinin B (NKB) and dynorphin (Dyn), forming the specialized KNDy neuron population that governs pulsatile GnRH secretion. Research indicates:

• NKB acts through NK3 receptors to stimulate kisspeptin release in an autosynaptic manner
• Dynorphin provides negative feedback by inhibiting kisspeptin neuron activity through kappa-opioid receptors
• This reciprocal regulation creates an oscillatory network responsible for GnRH pulse generation
• Kisspeptin-10 administration can override endogenous pulse patterns and increase pulse frequency

The KNDy neuron network appears critical for mediating negative steroid feedback on the reproductive axis, with estrogen and testosterone suppressing kisspeptin expression in these neurons.

Sex Steroid Receptor Integration – Feedback Regulation

Kisspeptin neurons express estrogen receptor alpha and androgen receptors, enabling direct integration of sex steroid signals. Studies show:

• Estrogen negatively regulates kisspeptin expression in arcuate nucleus neurons (negative feedback)
• Estrogen positively regulates kisspeptin expression in anteroventral periventricular nucleus neurons in females (positive feedback for LH surge)
• Testosterone suppresses kisspeptin signaling in males, mediating negative feedback on gonadotropin secretion
• Sexual dimorphism exists in kisspeptin neuron distribution and hormone responsiveness between males and females

This dual regulation allows kisspeptin to mediate both the tonic restraint and the preovulatory surge mechanisms essential for normal reproductive cyclicity.

Metabolic Sensor Integration – Energy Balance Coupling

Research demonstrates that kisspeptin neurons receive and integrate metabolic signals to coordinate reproduction with energy availability:

• Expression of leptin receptors on kisspeptin neurons enables sensing of nutritional status
• Insulin receptor signaling in kisspeptin neurons links glucose homeostasis to reproductive function
• Ghrelin and other orexigenic peptides modulate kisspeptin neuron activity
• Chronic energy deficit or obesity can suppress kisspeptin signaling, contributing to reproductive dysfunction

Studies in fasted animals show preserved or even enhanced LH responses to exogenous kisspeptin-10 despite suppressed endogenous tone, suggesting compensatory receptor upregulation during negative energy balance.

Peripheral Actions – Pancreas, Gonads, and Cardiovascular System

Beyond hypothalamic actions, kisspeptin-10 and KISS1R are expressed in peripheral tissues where they may exert direct effects:

• Pancreatic islets: Kisspeptin-10 enhances glucose-induced insulin secretion from beta cells in primate and rodent studies
• Testes and sperm: KISS1R expression in spermatozoa with effects on motility and intracellular calcium
• Cardiac fibroblasts: Kisspeptin-10 increases collagen deposition through focal adhesion kinase activation
• Vasculature: Potential vasoconstrictor and angiogenesis-inhibitory effects in some vascular beds

Kisspeptin-10 Research Applications & Key Findings

Reproductive Neuroendocrinology Research

Gonadotropin-Releasing Hormone Stimulation

Extensive research in multiple species has established kisspeptin-10 as one of the most potent stimulators of GnRH-induced gonadotropin secretion. Key findings include:

• Dose-dependent LH and FSH release in rodents, primates, and humans following intravenous administration
• In healthy men, doses as low as 0.3 nmol/kg intravenously significantly elevated serum LH within 30 minutes
• Rapid onset of action with LH responses detected within 10-15 minutes of administration
• Continuous infusion studies in men demonstrated sustained LH pulse frequency increases over 22.5 hours
• Peak LH responses typically 2-3 fold above baseline following bolus administration

Human studies revealed that kisspeptin-10 stimulation is more potent in males than in females during the follicular phase, suggesting sex-specific sensitivity differences in the hypothalamic-pituitary axis.

Puberty and Sexual Maturation Research

Studies in juvenile animals have provided critical insights into kisspeptin-10’s role in pubertal development:

• Repeated administration of kisspeptin-10 to prepubertal rats induced precocious puberty with earlier vaginal opening and first estrus
• Hypothalamic kisspeptin expression increases dramatically during the pubertal transition across species
• Mutations in KISS1 or KISS1R genes in humans cause idiopathic hypogonadotropic hypogonadism with absent or incomplete puberty
• Kisspeptin antagonists delay pubertal onset in animal models

Research indicates that increasing kisspeptin tone serves as a critical trigger initiating the cascade of pubertal development.

Reproductive Disorder Models

Hypothalamic Amenorrhea and Infertility

Kisspeptin-10 has been investigated as both a diagnostic tool and potential therapeutic agent in reproductive disorders:

• Administration to women with hypothalamic amenorrhea induced gonadotropin responses, demonstrating intact pituitary function despite suppressed endogenous GnRH drive
• Studies in women with functional hypothalamic amenorrhea showed that kisspeptin can restore gonadotropin pulsatility
• Research in polycystic ovary syndrome models examined whether altered kisspeptin signaling contributes to elevated LH pulse frequency
• Kisspeptin diagnostic testing may differentiate hypothalamic versus pituitary causes of hypogonadism

IVF and Ovulation Induction Research

Clinical trials have explored kisspeptin-54 (the longer isoform) for triggering oocyte maturation in women undergoing in vitro fertilization, with research on kisspeptin-10 analogs ongoing:

• Kisspeptin administration can induce an LH surge sufficient for oocyte maturation while avoiding ovarian hyperstimulation syndrome
• Novel kisspeptin receptor agonists based on the kisspeptin-10 structure show prolonged duration of action
• Studies suggest kisspeptin-triggered oocyte maturation may offer a more physiological alternative to human chorionic gonadotropin

Behavioral and Mood Research

Sexual Brain Processing and Arousal

Recent human neuroimaging studies have revealed kisspeptin’s effects beyond the hypothalamus:

• Functional MRI studies in men showed kisspeptin-10 administration enhanced brain activity in limbic and paralimbic regions in response to sexual stimuli
• Research in men with hypoactive sexual desire disorder demonstrated kisspeptin increased sexual brain processing and improved penile tumescence responses
• Studies suggest kisspeptin modulates sexual behavior through GnRH-independent pathways involving kisspeptin neurons projecting to brain reward centers
• Animal research has identified kisspeptin’s role in regulating lordosis behavior in female rodents through ventromedial hypothalamic circuits

Metabolic Regulation Research

Pancreatic Function and Insulin Secretion

Studies have examined kisspeptin-10’s peripheral metabolic effects, particularly in pancreatic islets:

• Kisspeptin-10 potentiated glucose-stimulated insulin secretion from isolated human and rodent islets without affecting basal secretion
• In vivo studies in rhesus monkeys and rats confirmed insulin-potentiating effects following peripheral administration
• Research suggests KISS1R activation in pancreatic beta cells may contribute to metabolic regulation
• Some studies report conflicting effects, with kisspeptin-13 showing inhibitory actions in certain models

Energy Balance and Body Weight

Investigations into kisspeptin’s metabolic sensing functions have revealed:

• Chronic stress and negative energy balance suppress hypothalamic kisspeptin expression in rodent models
• Food deprivation paradoxically enhances LH responsiveness to exogenous kisspeptin-10 despite suppressed endogenous tone
• Metabolomic studies show kisspeptin-10 administration alters carbohydrate and amino acid metabolism pathways
• Obesity and metabolic disorders are associated with altered kisspeptin signaling, potentially linking reproductive and metabolic dysfunction

Kisspeptin-10 Pharmacokinetics & Metabolism

Absorption & Distribution

Kisspeptin-10 exhibits characteristic pharmacokinetic properties for a short peptide, with research demonstrating rapid systemic distribution following administration. Studies in humans and animals indicate:

• Intravenous administration results in immediate systemic circulation with peak plasma levels within 1-2 minutes
• Subcutaneous administration in women showed delayed absorption compared to intravenous routes with altered concentration-time profiles
• Plasma kisspeptin immunoreactivity increased dose-dependently following bolus injection in human studies
• Evidence suggests kisspeptin can cross the blood-brain barrier, as peripheral administration activates central GnRH neurons and induces behavioral effects

Distribution studies using radiolabeled peptide in animals showed widespread tissue distribution with concentration in reproductive tissues and the hypothalamus.

Metabolism & Elimination

The metabolic fate of kisspeptin-10 is characterized by extremely rapid degradation, representing a significant pharmacokinetic limitation:

• Plasma half-life of 3.8-4.1 minutes in healthy human volunteers following intravenous administration
• In vitro stability studies in rat plasma at 37 degrees C showed an initial degradation half-life of only 1.7 minutes
• More than 90% of kisspeptin-10 degraded within 30 minutes in rat plasma under physiological conditions
• Temperature-dependent degradation with faster breakdown at higher temperatures

Metabolic pathway analysis revealed:

• Primary degradation product is the N-terminal tyrosine-deleted peptide, indicating peptidase cleavage at the N-terminus
• Additional cleavage products include kisspeptin-9, -7, and -4 fragments
• Enzymatic degradation by plasma peptidases represents the major clearance mechanism
• The first amino acid residue (tyrosine) appears particularly susceptible to proteolytic cleavage

Despite the extremely short plasma half-life, biological effects on LH secretion persist for 30-60 minutes or longer, suggesting either tissue retention, active metabolites contributing to effects, or persistent downstream signaling after initial receptor activation.

Excretion Pathways

Limited data exists on specific excretion routes for kisspeptin-10 and its metabolites:

• Renal elimination of peptide fragments likely represents a major excretion pathway given the small molecular weight
• Calculated metabolic clearance rate of approximately 3.2 ml/kg/min in human studies
• Volume of distribution approximately 129 ml/kg, suggesting limited extravascular distribution
• No evidence of accumulation with repeated administration in animal studies

The profound discrepancy between the ultra-short plasma half-life and the prolonged duration of biological effects represents an important area requiring further mechanistic investigation.

Kisspeptin-10 Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse kisspeptin-10 doses depending on species, study objectives, and administration route:

• Human studies (males): 0.01-10 nmol/kg for bolus injections; 20-720 pmol/kg/min for continuous infusions
• Human studies (females): 0.01-10 nmol/kg for bolus injections; 20-720 pmol/kg/min for continuous infusions
• Rat studies: 1-10 micrograms/kg for acute studies; 1-10 micrograms per animal for repeated dosing protocols
• Mouse studies: 0.15-1 nmol per animal for subcutaneous or intraperitoneal injection
• Primate studies: 1-10 micrograms/kg for rhesus monkey research

Important: These are experimental doses used in animal and human research studies and cannot be extrapolated to other species or contexts due to significant differences in metabolism, receptor expression, pharmacokinetics, peptide stability, and physiological responses. Species-specific factors, including differences in peptidase activity and receptor density, profoundly influence both efficacy and safety profiles.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical and clinical studies:

• Intravenous bolus – Most common route in human studies; provides rapid onset and predictable pharmacokinetics
• Intravenous infusion – Used to study continuous stimulation effects and maintain steady-state kisspeptin levels
• Subcutaneous injection – Investigated in women for potential outpatient applications; shows delayed absorption kinetics
• Intraperitoneal injection – Standard route for rodent studies; reliable systemic delivery
• Intracerebroventricular injection – Used in animal studies to examine direct central nervous system effects
• Intranasal administration – Explored in some animal studies but not extensively characterized

Common Model Organisms

Kisspeptin-10 has been studied across multiple species to understand its comparative biology:

• Humans – Clinical trials in healthy volunteers and patients with reproductive disorders; largest body of safety data
• Rats (Wistar, Sprague-Dawley strains) – Most extensively used rodent model; majority of mechanistic studies
• Mice (C57BL/6, knockout models) – Used for genetic studies and mechanism investigations
• Rhesus monkeys – Primate model for translational reproductive studies
• Sheep – Important model for reproductive neuroendocrinology research
• Cell culture systems – CHO cells stably expressing KISS1R, human pancreatic islets, cardiac fibroblasts, GnRH neurons

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite extensive research over two decades, kisspeptin-10 faces several important limitations that constrain its research utility and clinical translation.

Human Clinical Data Limitations

While kisspeptin-10 has been administered to human subjects in multiple clinical trials, significant gaps remain:

• Limited long-term safety data beyond short-term administration in controlled research settings
• Most human studies have used kisspeptin-54 (the longer isoform); fewer studies specifically with kisspeptin-10
• Optimal dosing regimens for various clinical applications remain undefined
• Potential for receptor desensitization with repeated administration documented in some studies
• Long-term efficacy for treating reproductive disorders not established in large-scale trials
• Pediatric safety data extremely limited

Mechanistic Understanding Gaps

Fundamental aspects of kisspeptin-10 biology require further clarification:

• Peripheral versus central actions: Relative contribution of direct peripheral effects versus central hypothalamic effects incompletely understood
• Mechanisms explaining the disconnect between ultra-short plasma half-life and prolonged biological effects unclear
• Tissue-specific signaling pathways and receptor coupling mechanisms in non-reproductive tissues poorly characterized
• Species differences in kisspeptin physiology may limit translatability of animal findings
• Role of kisspeptin metabolites and whether they possess biological activity unknown

Long-Term Safety Considerations

Critical safety questions remain unanswered for extended kisspeptin-10 use:

• Chronic administration effects beyond several weeks unstudied in humans
• Potential impact on reproductive axis function with prolonged exposure unclear
• Effects on non-reproductive systems including cardiovascular, metabolic, and bone health require investigation
• Interaction potential with other medications not systematically evaluated
• Effects in special populations including pregnancy, lactation, and children largely unknown
• Potential for antibody development with repeated administration not characterized

Regulatory & Competitive Sport Status

FDA Position

Kisspeptin-10 has limited regulatory status for human use:

• No FDA approval for any clinical indication
• Investigated as an experimental agent in clinical trials under Investigational New Drug applications
• Not recognized as generally recognized as safe (GRAS) for food use
• Not approved for compounding in pharmacy settings for patient use
• Synthetic analogs with improved pharmacokinetic properties under clinical development

The FDA Pharmacy Compounding Advisory Committee has reviewed kisspeptin-10 but has not recommended it for inclusion on the bulk substances list for compounding due to limited human safety data and the availability of FDA-approved alternatives for reproductive indications.

WADA Status

The World Anti-Doping Agency has not specifically listed kisspeptin-10 as a prohibited substance as of current information:

• Kisspeptins are endogenous hormones, complicating anti-doping testing
• Potential performance effects through testosterone modulation in males theoretically possible
• No established detection methods for exogenous kisspeptin administration in biological samples
• Athletes should verify current WADA prohibited substance list as regulations may change

Research Classification: Kisspeptin-10 is available only for laboratory research use by qualified investigators. It is not intended for human consumption outside approved clinical trials, medical use, veterinary applications, or sports performance enhancement. All research must be conducted under appropriate ethical oversight with institutional review board approval and informed consent where applicable.

References

1. Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, Brézillon S, Tyldesley R, Suarez-Huerta N, Vandeput F, Blanpain C, Schiffmann SN, Vassart G, Parmentier M. (2001). The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Journal of Biological Chemistry, 276(37), 34631-34636. PubMed
   
2. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, Ishibashi Y, Watanabe T, Asada M, Yamada T, Suenaga M, Kitada C, Usuki S, Kurokawa T, Onda H, Nishimura O, Fujino M. (2001). Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature, 411(6837), 613-617. PubMed
   
3. Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, McGowan BM, Amber V, Patel S, Ghatei MA, Bloom SR. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism, 90(12), 6609-6615. PubMed
   
4. Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, Patel D, Mehta A, Todd C, Ramachandran R, Salem V, Stamp GW, Donaldson M, Ghatei MA, Bloom SR, Dhillo WS. (2011). Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. Journal of Clinical Endocrinology & Metabolism, 96(8), 2320-2328. PubMed
   
5. George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, Anderson RA. (2011). Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. Journal of Clinical Endocrinology & Metabolism, 96(8), E1228-E1236. PubMed
   
6. Jayasena CN, Comninos AN, Stefanopoulou E, Buckley A, Narayanaswamy S, Izzi-Engbeaya C, Abbara A, Ratnasabapathy R, Mogford J, Ng N, Sarang Z, Ghatei MA, Bloom SR, Dhillo WS. (2014). Neurokinin B administration induces hot flushes in women. Scientific Reports, 4, 5859. PubMed
   
7. Navarro VM, Castellano JM, Fernández-Fernández R, Barreiro ML, Roa J, Sanchez-Criado JE, Aguilar E, Dieguez C, Pinilla L, Tena-Sempere M. (2004). Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor, GPR54, in rat hypothalamus and potent luteinizing hormone-releasing activity of KiSS-1 peptide. Endocrinology, 145(10), 4565-4574. PubMed
   
8. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O’Rahilly S, Carlton MB, Crowley WF Jr, Aparicio SA, Colledge WH. (2003). The GPR54 gene as a regulator of puberty. New England Journal of Medicine, 349(17), 1614-1627. PubMed
   
9. Messager S, Chatzidaki EE, Ma D, Hendrick AG, Zahn D, Dixon J, Thresher RR, Malinge I, Lomet D, Carlton MB, Colledge WH, Caraty A, Aparicio SA. (2005). Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proceedings of the National Academy of Sciences USA, 102(5), 1761-1766. PubMed
   
10. Roseweir AK, Kauffman AS, Smith JT, Guerriero KA, Morgan K, Pielecka-Fortuna J, Pineda R, Gottsch ML, Tena-Sempere M, Moenter SM, Terasawa E, Clarke IJ, Steiner RA, Millar RP. (2009). Discovery of potent kisspeptin antagonists delineate physiological mechanisms of gonadotropin regulation. Journal of Neuroscience, 29(12), 3920-3929. PubMed
    
11. Bhattacharya M, Babwah AV. (2015). Kisspeptin: beyond the brain. Endocrinology, 156(4), 1218-1227. PubMed
    
12. Dudek M, Ziarniak K, Sliwowska JH. (2018). Kisspeptin and metabolism: the brain and beyond. Frontiers in Endocrinology, 9, 145. PubMed
    
13. Hauge-Evans AC, Richardson CC, Milne HM, Christie MR, Persaud SJ, Jones PM. (2006). A role for kisspeptin in islet function. Diabetologia, 49(9), 2131-2135. PubMed
    
14. Wahab F, Ullah F, Chan YM, Seminara SB, Shahab M. (2011). Increase in hypothalamic and serum kisspeptin levels and gonadotropic responses by oestrogen in premenarchal rhesus monkeys (Macaca mulatta). Journal of Neuroendocrinology, 23(6), 518-525. PubMed
    
15. Castellano JM, Navarro VM, Fernández-Fernández R, Nogueiras R, Tovar S, Roa J, Vazquez MJ, Vigo E, Casanueva FF, Aguilar E, Pinilla L, Dieguez C, Tena-Sempere M. (2005). Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition. Endocrinology, 146(9), 3917-3925. PubMed
    
16. Navarro VM, Fernández-Fernández R, Castellano JM, Roa J, Mayen A, Barreiro ML, Gaytan F, Aguilar E, Pinilla L, Dieguez C, Tena-Sempere M. (2004). Advanced vaginal opening and precocious activation of the reproductive axis by KiSS-1 peptide, the endogenous ligand of GPR54. Journal of Physiology, 561(Pt 2), 379-386. PubMed
    
17. Tomikawa J, Homma T, Tajima S, Shibata T, Inamoto Y, Takase K, Inoue N, Ohkura S, Uenoyama Y, Maeda K, Tsukamura H. (2010). Molecular characterization and estrogen regulation of hypothalamic KISS1 gene in the pig. Biology of Reproduction, 82(2), 313-319. PubMed
    
18. Mills EG, Dhillo WS, Comninos AN. (2018). Kisspeptin and the control of emotions, mood and reproductive behaviour. Journal of Endocrinology, 239(1), R1-R12. PubMed
    
19. Comninos AN, Wall MB, Demetriou L, Shah AJ, Clarke SA, Dhillo WS. (2017). Kisspeptin modulates sexual and emotional brain processing in humans. Journal of Clinical Investigation, 127(2), 709-719. PubMed
    
20. Mills EG, Ertl N, Wall M, Thurston L, Yang L, Suladze S, Hunjan T, Phylactou M, Patel B, Muzi B, Ettehad D, Bassett P, Howard J, Rabiner E, Bech P, Abbara A, Goldmeier D, Comninos AN, Dhillo WS. (2023). Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Network Open, 6(3), e231145. PubMed
    
21. Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA. (2020). Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome. Human Reproduction, 35(6), 1421-1431. PubMed
    
22. Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, Comninos AN, Peters D, Buckley A, Ratnasabapathy R, Prague JK, Salim R, Lavery SA, Bloom SR, Szigeti M, Ashby DA, Trew GH, Dhillo WS. (2015). Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. Journal of Clinical Endocrinology & Metabolism, 100(9), 3322-3331. PubMed
    
23. Abbara A, Eng PC, Phylactou M, Clarke SA, Hunjan T, Valli H, Tan T, Mills E, Comninos AN, Dhillo WS. (2023). Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. Journal of Clinical Investigation, 133(10), e161515. PubMed
    
24. Jayasena CN, Abbara A, Veldhuis JD, Comninos AN, Ratnasabapathy R, De Silva A, Nijher GM, Ganiyu-Dada Z, Vaal M, Stamp G, Ghatei MA, Bloom SR, Dhillo WS. (2014). Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. Journal of Clinical Endocrinology & Metabolism, 99(6), E953-E961. PubMed
    
25. Izzi-Engbeaya C, Comninos AN, Clarke SA, Jomard A, Yang L, Jones S, Abbara A, Narayanaswamy S, Eng PC, Papadopoulou D, Prague JK, Bech P, Godsland IF, Bassett P, Sands C, Camuzeaux S, Gomez-Romero M, Pearce JTM, Lewis MR, Dhillo WS. (2016). The effects of kisspeptin on beta-cell function, serum metabolites and appetite in humans. Diabetes, Obesity and Metabolism, 20(12), 2800-2810. PubMed
    
26. Anasti JN, Flack MR, Froehlich J, Nelson LM, Nisula BC. (1995). The use of human recombinant gonadotropin receptors to search for immunoglobulin G-mediated premature ovarian failure. Journal of Clinical Endocrinology & Metabolism, 80(3), 824-828. PubMed
    
27. Feng Y, Weijdegård B, Wang T, Egecioglu E, Fernandez-Rodriguez J, Huhtaniemi I, Stener-Victorin E, Billig H, Shao R. (2013). Spatiotemporal expression of androgen receptors in the female rat brain during the oestrous cycle and the impact of exogenous androgen administration: a comparison with gonadally intact males. Molecular and Cellular Endocrinology, 369(1-2), 85-97. PubMed
    
28. Iwasa T, Matsuzaki T, Murakami M, Fujisawa S, Kinouchi R, Gereltsetseg G, Nakazawa H, Kusaka T, Kuwahara A, Shibata S, Irahara M. (2010). Effects of intrauterine undernutrition on hypothalamic Kiss1 expression and the timing of puberty in female rats. Journal of Physiology, 588(Pt 5), 821-829. PubMed
    
29. Pielecka-Fortuna J, Chu Z, Moenter SM. (2008). Kisspeptin acts directly and indirectly to increase gonadotropin-releasing hormone neuron activity and its effects are modulated by estradiol. Endocrinology, 149(4), 1979-1986. PubMed
    
30. Roa J, Vigo E, Castellano JM, Navarro VM, Fernández-Fernández R, Casanueva FF, Dieguez C, Aguilar E, Pinilla L, Tena-Sempere M. (2006). Hypothalamic expression of KiSS-1 system and gonadotropin-releasing effects of kisspeptin in different reproductive states of the female rat. Endocrinology, 147(6), 2864-2878. PubMed
    
31. Qiu J, Nestor CC, Zhang C, Padilla SL, Palmiter RD, Kelly MJ, Rønnekleiv OK. (2016). High-frequency stimulation-induced peptide release synchronizes arcuate kisspeptin neurons and excites GnRH neurons. eLife, 5, e16246. PubMed
    
32. Wahab F, Atika B, Shahab M, Behr R. (2016). Kisspeptin signalling in the physiology and pathophysiology of the urogenital system. Nature Reviews Urology, 13(1), 21-32. PubMed
    
33. Tolson KP, Garcia C, Yen S, Simonds S, Stefanidis A, Lawrence A, Smith JT, Kauffman AS. (2014). Impaired kisspeptin signaling decreases metabolism and promotes glucose intolerance and obesity. Journal of Clinical Investigation, 124(7), 3075-3079. PubMed
    
34. Roa J, García-Galiano D, Varela L, Sánchez-Garrido MA, Pineda R, Castellano JM, Ruiz-Pino F, Romero M, Aguilar E, López M, Gaytan F, Diéguez C, Pinilla L, Tena-Sempere M. (2009). The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system. Endocrinology, 150(11), 5016-5026. PubMed
    
35. Xu Y, Nedungadi TP, Zhu L, Sobhani N, Irani BG, Davis KE, Zhang X, Zou F, Gent LM, Hahner LD, Khan SA, Elias CF, Elmquist JK, Clegg DJ. (2011). Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metabolism, 14(4), 453-465. PubMed
    
36. Curtis AE, Cooke JH, Baxter JE, Parkinson JR, Bataveljic A, Ghatei MA, Bloom SR, Murphy KG. (2010). A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10. American Journal of Physiology – Endocrinology and Metabolism, 298(2), E296-E303. PubMed
    
37. Jayasena CN, Comninos AN, Nijher GM, Abbara A, De Silva A, Veldhuis JD, Ratnasabapathy R, Izzi-Engbeaya C, Lim A, Patel DA, Ghatei MA, Bloom SR, Dhillo WS. (2013). Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers. Journal of Clinical Endocrinology & Metabolism, 98(11), 4464-4474. PubMed
    
38. Ning Y, Ma D, Kuang H, Xiao X. (2022). LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 and characterization of its decomposition product and pharmacokinetics in rats. Journal of Chromatography B, 987, 16-24. PubMed
    
39. Ramaswamy S, Seminara SB, Ali B, Ciofi P, Amin NA, Plant TM. (2010). Neurokinin B stimulates GnRH release in the male monkey (Macaca mulatta) and is colocalized with kisspeptin in the arcuate nucleus. Endocrinology, 151(9), 4494-4503. PubMed
    
40. Clarkson J, Herbison AE. (2006). Postnatal development of kisspeptin neurons in mouse hypothalamus; sexual dimorphism and projections to gonadotropin-releasing hormone neurons. Endocrinology, 147(12), 5817-5825. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Kisspeptin-10 is intended for laboratory research use only.